Format

Send to

Choose Destination
Hum Mutat. 2013 Sep;34(9):1231-41. doi: 10.1002/humu.22346. Epub 2013 Jun 3.

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.

Author information

1
Cancer and Inflammation Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA.

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease, and molecular markers that differentiate indolent from aggressive subtypes are needed. We sequenced the exomes of five metastatic tumors and healthy kidney tissue from an index case with mCRPC to identify lesions associated with disease progression and metastasis. An Ashkenazi Jewish (AJ) germline founder mutation, del185AG in BRCA1, was observed and AJ ancestry was confirmed. Sixty-two somatic variants altered proteins in tumors, including cancer-associated genes, TMPRSS2-ERG, PBRM1, and TET2. The majority (n = 53) of somatic variants were present in all metastases and only a subset (n = 31) was observed in the primary tumor. Integrating tumor next-generation sequencing and DNA copy number showed somatic loss of BRCA1 and TMPRSS2-ERG. We sequenced 19 genes with deleterious mutations in the index case in additional mCRPC samples and detected a frameshift, two somatic missense alterations, tumor loss of heterozygosity, and combinations of germline missense SNPs in TET2. In summary, genetic analysis of metastases from an index case permitted us to infer a chronology for the clonal spread of disease based on sequential accrual of somatic lesions. The role of TET2 in mCRPC deserves additional analysis and may define a subset of metastatic disease.

KEYWORDS:

BRCA1; ERG; PBRM1; TET2; TMPRSS2; epigenetic modifiers; metastasis; somatic mutation; tumor heterogeneity

PMID:
23636849
PMCID:
PMC3745530
DOI:
10.1002/humu.22346
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center